{"name":"Arbor Pharmaceuticals, Inc.","slug":"arbor-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2005-01-01","label":"BiDil XR first approved","drug":"BiDil XR","drugSlug":"bidil-xr","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"AR10","genericName":"AR10","slug":"ar10","indication":"Other","status":"phase_1"},{"name":"AR11","genericName":"AR11","slug":"ar11","indication":"Other","status":"marketed"},{"name":"BiDil XR","genericName":"BiDil XR","slug":"bidil-xr","indication":"Other","status":"marketed"},{"name":"Glycerin ear drops","genericName":"Glycerin ear drops","slug":"glycerin-ear-drops","indication":"Acute otitis media with effusion","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Azilsartan Medoxomil Low-dose","genericName":"Azilsartan Medoxomil Low-dose","slug":"azilsartan-medoxomil-low-dose","indication":"Hypertension","status":"phase_3"},{"name":"Placebo for Azilsartan Medoxomil","genericName":"Placebo for Azilsartan Medoxomil","slug":"placebo-for-azilsartan-medoxomil","indication":"Control arm in phase 3 trials for azilsartan medoxomil (angiotensin II receptor antagonist for hypertension)","status":"phase_3"}]}],"pipeline":[{"name":"Azilsartan Medoxomil Low-dose","genericName":"Azilsartan Medoxomil Low-dose","slug":"azilsartan-medoxomil-low-dose","phase":"phase_3","mechanism":"Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to reduce blood pressure.","indications":["Hypertension"],"catalyst":""},{"name":"Placebo for Azilsartan Medoxomil","genericName":"Placebo for Azilsartan Medoxomil","slug":"placebo-for-azilsartan-medoxomil","phase":"phase_3","mechanism":"This is a placebo control with no active pharmacological mechanism.","indications":["Control arm in phase 3 trials for azilsartan medoxomil (angiotensin II receptor antagonist for hypertension)"],"catalyst":""},{"name":"AR10","genericName":"AR10","slug":"ar10","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AR11","genericName":"AR11","slug":"ar11","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BiDil XR","genericName":"BiDil XR","slug":"bidil-xr","phase":"marketed","mechanism":"BiDil XR combines isosorbide dinitrate and hydralazine to enhance vasodilation and reduce cardiac workload, specifically benefiting patients with heart failure.","indications":[],"catalyst":""},{"name":"Glycerin ear drops","genericName":"Glycerin ear drops","slug":"glycerin-ear-drops","phase":"phase_3","mechanism":"Glycerin ear drops work by drawing fluid out of the middle ear through osmotic action, reducing pressure and relieving ear discomfort.","indications":["Acute otitis media with effusion","Serous otitis media (otitis media with effusion)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5fYVV3YzYxSVdYLWk5RGd6cWVZa1RsZDEydDBzS0cza1lqT1lJay1tWUZ6S1pFYm5wZTlRcjExczY5OHE3bWRwVzZXWWJvaXZ4WmpQSGhpdjR2UkQwbWNHb25XUUM3OGZUeDZGM2JxTkZFYVJzVWNHWQ?oc=5","date":"2026-03-24","type":"trial","source":"Market Data Forecast","summary":"Glioblastoma Market Size, Share & Growth Report, 2034 - Market Data Forecast","headline":"Glioblastoma Market Size, Share & Growth Report, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxOTGxmOVlOUUd0ZmFpLTYxSHhFdGRNZFVTbGRscmhMOExwbXVsVDQyUVlrREZTaDZ6MVN4VDRndTB3ZkZ0cHp6OC1vZjJEZFRZN0d6MWdPak5OTzVyZkNzMnlUZTg0U3R2SlYzMWd5bXNuMTVKdEZBM2V5Y21FTHRqY0k0ODZKS21VZEVfWTJRVkxRWjBOVllYV3piUmNNRERGb2FORU9NX0g2bzZrNzdFcV9GZGEzTS05TGRtclYwQWdPa1piTjNmZlNFdGlpV3NCODdfQXpPbjgybURaR08yQzVrb3EtMURHLXNNZWE2ZzJxcFA3ZjRBclEzbGZRM1BJbjdKRnRoYm05QW1jYTl1SzEtRnBTSF9INEUzNkxqVUVWZkFXaldxXw?oc=5","date":"2026-01-22","type":"earnings","source":"PR Newswire","summary":"Arbor Scientia Group Introduces an Innovative Educational Strategy to Assist Their Pharmaceutical Clients in Driving Measurable Learning Outcomes - PR Newswire","headline":"Arbor Scientia Group Introduces an Innovative Educational Strategy to Assist Their Pharmaceutical Clients in Driving Mea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNSUM0aHNqUFUxZTNvc2c4cno1ZHhXcFV2QjgzVkdnd0xxQ0RSMThFQks5Z1lTZ2RNVmp3V0tONC11UGxGdkRUUE9oZzB3WUJxQUV6ZXVhNV9YWEJNV0xMeTRkajRnbnhqMGxSQWtvZHAxeDF3ODdDYVJENm1aOGwtNUstU0hfTVg1bFBxLXNCeXdpSU9FUHQ2c0pGRHFMZzhXUjhWOQ?oc=5","date":"2025-10-06","type":"deal","source":"BioPharma Dive","summary":"Chiesi buys into Arbor gene editing drug for rare kidney disease - BioPharma Dive","headline":"Chiesi buys into Arbor gene editing drug for rare kidney disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxOZFFXbjY5X19SVW9xSlRDdjdlUkgzYnRNbnFFRzU5WjBwUXpyS2xYRm5Sd2sxWndTZ3RpOHFiNEJjbU1CXzg1M3hwSkN5TW1tY05TZG5BMmtGNmZNS1F5WGRxR3F5MzhqSnRzWndvaS0zMGgxQWdfU2VwU1V2ckZxYVVEOGxDRlMzTEVsZm5yU045QWhLWURlTXdRcFhXSXZTb0h0WjVBMklWTTNLVG5hdm04MG1hWUJXUEdUSFlnZHNPT2VuNlFkNXEtVGNXc1FPang4Q09JOVVKMjNTYjB2ZHd3QlVlUC13ZkR2RG5OV0llZ3hicUg5SjdPc1lieXE4eUR0X2lnRTY0SUlDTzRPV1dpQU1tMWRDYjZGTGh1enZpS1RJa2w1SWRtbWF4dw?oc=5","date":"2025-06-26","type":"trial","source":"GlobeNewswire","summary":"Autism Spectrum Disorder Clinical Trial Analysis: Key - GlobeNewswire","headline":"Autism Spectrum Disorder Clinical Trial Analysis: Key","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFBZQm9WbGw0SmlPV0JjV0tjY0h5R0dRYzc4NVpOaGdzMEdnRlhDNmxsaEVILTh5bWN0Z2kzX0FzRmhseGh2R1FXd3Y1M1dWekdsdlVFY183OEREbFNoZWhwQW9uMDNrWlRJOUhB?oc=5","date":"2024-10-01","type":"pipeline","source":"Georgia Department of Economic Development","summary":"Georgia’s Life Sciences Make an Impact - Georgia Department of Economic Development","headline":"Georgia’s Life Sciences Make an Impact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5ZMTJtcjZOb0Jwc0E2ZjJ5YTBITGtucE45NFRhN0dIbC1Zam1sU004bWxlNk9KbnNFcmN6QUEzRlctMWpGR28wME1ZSEQyeFNBZHRIY0kyR1EzaFVGMnRxVW9HZXpUT0Q2ZjFWWURfbk5GSUgxVkE?oc=5","date":"2024-07-17","type":"pipeline","source":"The Pharma Letter","summary":"Arbor Pharmaceuticals - The Pharma Letter","headline":"Arbor Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE03blBhczVDNTZ1dWZYMm41MXBITTc2ck5xUG9MRy1fcVB6dUFZTkNqZ2lSaW9XRGFPMHVaVTJGT2VNWGhoc3dGWnpvUWtZVEtyNmVCdHZnZ011TW9FT19uTHhTMUloRlZJNWc?oc=5","date":"2024-05-15","type":"pipeline","source":"Built In","summary":"21 Top Pharma Companies in India to Know - Built In","headline":"21 Top Pharma Companies in India to Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNZndDVkg4a0t3cHRncDN3M2dYbnFPYWhkblpYVEJod2FPNF94blJwa3hkY0JCaU5BdDF4ZUJKc3p5eFZwWk95ZnRQUGQ0REhHSUVjUDVINmg1dkFlNXhsWS1wR0hDbDI2dlltd3RVTHFaNGRfVlJ0blkzZXZSeGFWR2R5Yng4NWRWS016N2lSbHlBZ2prU25nUmdrcVZNUi1V?oc=5","date":"2022-10-17","type":"deal","source":"The Business Journals","summary":"Deals of the Year: Alora Pharmaceutical buys Osmotica Pharmaceutical for $111M - The Business Journals","headline":"Deals of the Year: Alora Pharmaceutical buys Osmotica Pharmaceutical for $111M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxOUjVTeVBPem5QenBUME53TWFZTTlYSm0zcjYwOWFGSkhSVWxvVFBrVWlhZmpja3R5QkVHZGFtTTEzODk0WGpNSFJjLWxrX2VNcmdLQUd3aXJCelN2MHlWcWQ4NFhZVHRfejRoMlpEUDJqbHdrTTJKRzZENzVyZEFnWU9CSVZDVUZ6VDdFUWxkOUl4bGNyV3lNWmExWG5BTzRoMDN6ZG9TZTNlSHIzZkNuMkxpTTVJWFNKelQ5OUU5T0ctZ2ItdWVDZlZicjctNlh0TWltYms1RUZZT0ZoUWdFZ3Npa1BzRFdvV2pkWERMM0FQR3F1ajhIRUxYeWZoYmtC?oc=5","date":"2022-01-04","type":"pipeline","source":"Business Wire","summary":"Intrance Medical Systems Completes $17 Million Series A Financing and Appoints Ed Schutter to Board of Directors - Business Wire","headline":"Intrance Medical Systems Completes $17 Million Series A Financing and Appoints Ed Schutter to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQTWtPeWpMR0pZb2xsQmJ2VTBQNkVyZXlSTzFKMHJNQndGa1QyeUZvUDRfNTc3NUdBLVNvSF9zdmhWcmRXczNrQ2ljN1Y2WHZsSVZNbHpveGpyblpjcC0xRm1HaWQteWg5anpCT1l1Y01SbUoyUURJYVI0OHRPOVZxLWlodkpPX0wtQUtBN1EzODdFSi1UUjdONm8yamh4TFJxLWRFYzdNUWtiaGJtOWRmUGcxWFZ1NEpESFphVThR?oc=5","date":"2020-05-15","type":"regulatory","source":"Medical Professionals Reference","summary":"FDA to Review Manipulation-Resistant Stimulant Med for ADHD - Medical Professionals Reference","headline":"FDA to Review Manipulation-Resistant Stimulant Med for ADHD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQTVltUXRkQkVocEdvWDFLQXNPVGJIemRUemZybTRmY05nRlktRmF5QVFDU004WUlybVRUd003aUgxNVY2SmFkYWFaWGZtWTZDV2R4TERSZW01VDdJSDVTdDhWMWNiMW4ySVdWc2pXVWJtVV9yRF9lRm9nY01yaGg5R3B0QW13bU9kazJhZzBXblVJaDFCa1RLclZtQlJ4VWtRZUZLX0Z0N2xKaW0zdFE?oc=5","date":"2017-01-19","type":"trial","source":"ProPublica","summary":"When a Study Cast Doubt on a Heart Pill, the Drug Company Turned to Tom Price - ProPublica","headline":"When a Study Cast Doubt on a Heart Pill, the Drug Company Turned to Tom Price","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOS1dYYnp1Q2xidERIeUpKaExieERjU1k3Y3dFQ1BzSTdRUFVPX2pENEdscTdGVGRTdVJfOEVOdFVJVjN3TmIySnFlLTJhNnZLTUhsR3hjcG4xamFFVFpleTVBYXlQUGhDbEh4NFNURlZxSUQ0VFdoUnNGUWUwaVVGVGdGd19hb0wzeC1jbGtCTlB2Wm91R3Vndy1EQkpDc19OdUE?oc=5","date":"2016-05-23","type":"deal","source":"Fierce Biotech","summary":"Arbor buys out struggling Horizant developer XenoPort for $467M - Fierce Biotech","headline":"Arbor buys out struggling Horizant developer XenoPort for $467M","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":3,"phase_1":1,"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}